{
    "clinical_study": {
        "@rank": "6525", 
        "arm_group": {
            "arm_group_label": "All subjects", 
            "arm_group_type": "Other", 
            "description": "all qualifying subjects will receive HBOC-201 (Hemopure) to treat their life-threatening anemia"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this expanded access study is to be able to provide treatment with HBOC-201\n      to patients with life-threatening anemia for whom blood is not an option.\n\n      HBOC-201 is not FDA approved for use in the United States, but is approved as an oxygen\n      carrier in South Africa and Russia."
        }, 
        "brief_title": "Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Anemia", 
        "condition_browse": {
            "mesh_term": "Anemia"
        }, 
        "detailed_description": {
            "textblock": "i. Initial Dose\n\n      For patients with a hemoglobin level less than 6 mg/dl, an initial dose of 32.5 g (one unit)\n      of HBOC 201 is recommended, to be followed by infusion of additional units as necessary to\n      achieve and maintain a total hemoglobin concentration above 6 g/dl, provided that the\n      patient's circulatory volume is properly controlled and will not impose an inappropriate\n      risk.\n\n      ii. Subsequent Doses\n\n      The need for additional dose administration should be assessed after each infusion as\n      clinically indicated.\n\n      Dosing will be stopped if any one of the following occurs:\n\n        -  resolution of critical ischemia\n\n        -  death\n\n        -  recovery of native Hemoglobin levels to > 6 g/dL,\n\n        -  evidence of reticulocytosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients > = 18 years of age\n\n          2. Patients with hemoglobin < = 8g/dL with with active bleeding, physiologic evidence of\n             critical ischemia, for example: elevated troponins, altered mental status, acute\n             renal failure, lactic acidosis or central nervous system supply dependency\n\n          3. Patients or their Legally Authorized Representatives who are able and willing to\n             provide informed consent\n\n        Exclusion Criteria:\n\n          1. Patients with known hypersensitivity or allergy to beef products\n\n          2. Patients with pre-existing uncontrolled hypertension, heart failure, renal failure,\n             circulatory hypervolemia or systemic mastocytosis (on a case by case and quality of\n             life determination)\n\n          3. Patients > 80 years of age (on a case by case and quality of life determination)\n\n          4. Patients who are eligible for blood transfusions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01881503", 
            "org_study_id": "E-12-454"
        }, 
        "intervention": {
            "arm_group_label": "All subjects", 
            "description": "HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.", 
            "intervention_name": "HBOC-201", 
            "intervention_type": "Biological", 
            "other_name": "Hemopure"
        }, 
        "intervention_browse": {
            "mesh_term": "HBOC 201"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "life-threatening anemia", 
            "blood alternative", 
            "HBOC"
        ], 
        "lastchanged_date": "January 16, 2014", 
        "link": {
            "url": "http://englewoodhospital.com/ms_clinical-trials_home.asp"
        }, 
        "location": {
            "contact": {
                "email": "jamie.ketas@ehmc.com", 
                "last_name": "Jamie Ketas", 
                "phone": "201-894-3418"
            }, 
            "facility": {
                "address": {
                    "city": "Englewood", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07631"
                }, 
                "name": "Englewood Hospital and Medical Center"
            }, 
            "investigator": {
                "last_name": "Aryeh Shander, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Expanded Access Protocol for the Treatment Use of HBOC-201", 
        "overall_contact": {
            "email": "aryeh.shander@ehmc.com", 
            "last_name": "Aryeh Shander, MD", 
            "phone": "201-894-3238"
        }, 
        "overall_contact_backup": {
            "email": "nisha.gandhi@ehmc.com", 
            "last_name": "Nisha Gandhi, MD", 
            "phone": "201-894-3675"
        }, 
        "overall_official": {
            "affiliation": "Englewood Hospital and Medical Center", 
            "last_name": "Aryeh Shander, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "subjects will receive HBOC-201 to treat life-threatening anemia", 
            "measure": "survival", 
            "safety_issue": "No", 
            "time_frame": "1 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01881503"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Englewood Hospital and Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "OPK Biotech LLC", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Englewood Hospital and Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}